GastroPlus在毒理領域的應用文章 （2012—2020）

導  讀

凡默谷技術部精取了2012-2020年10月GastroPlus在毒理領域的應用文章28篇。

其中編號1-9的文章是2019年8月-2020年10月新增的文章。

希望對您的業務或專業學習有所幫助。內容如下：

1.   除草劑綠草定在哺乳動物中的藥代動力學和代謝研究：評估對安全性的影響

Review of the pharmacokinetics and metabolism of triclopyr herbicide in mammals: Impact on safety assessments.

Bartels M, Brown C, Chung G, Chan M, Terry C, Gehen SC, Corvaro M. Regulatory Toxicology and Pharmacology. Volume 116, October 2020, 104714. IF=2.652

2.   結構和PK功能的類似物在開發和評估生理藥代動力學PBPK模型中的應用

Application of structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic model development and evaluation.

Ellison CA, Wu S. Regul Toxicol Pharmacol. Volume 114, July 2020. IF=2.652

3.  整合3D培養的HepaRG細胞的體外數據和生理藥代動力學PBPK模型，評估對乙酰氨基酚的肝毒性

Integration of in vitro data from three dimensionally cultured HepaRG cells and physiologically based pharmacokinetic modeling for assessment of acetaminophen hepatotoxicity.

Zhang C, Zhang Q, Li J, Yu L, Li F, Li W, Li Y, Peng H, Zhao J, Carmichael PL, Wang Y, Peng S, Guo J. Regul Toxicol Pharmacol. Volume 114, July 2020. IF= 2.652

4.  評估化妝品中香豆素風險的新一代案例

A next generation risk assessment case study for coumarin in cosmetic products.

Baltazar MT, Cable S, Carmichael PL, Cubberley R, Cull TA, Delagrange M, Dent MP, Hatherell S, Houghton J, Kukic P, Li H, Lee MY, Malcomber S, Middleton AM, Moxon TE, Nathanail AV, Nicol B, Pendlington R, Reynolds GK, Reynolds J, White A, Westmoreland C. Toxicol Sci. 2020 Jul 1;176(1):236-252. IF= 3.703

5.  聯合體外代謝組學和生理藥代動力學建?？疾烊f古霉素引發的腎毒性

New insights into the vancomycin‐induced nephrotoxicity using in vitro metabolomics combined with physiologically based pharmacokinetic modeling.

Haiyan Du, Zheng Li, Yi Yang, Xiao Li, Yongxiang We, Yang Lin, Xiaomei Zhuang. J Appl Toxicol. 2020;40:897–907. IF=2.997

6.  結合體外測試和生理藥代動力學PBPK模型進行化學品的肝毒性評估–以曲格列酮作為案例研究

Integrating In Vitro Testing and Physiologically-Based Pharmacokinetic (PBPK) Modelling for Chemical Liver Toxicity Assessment – a Case Study of Troglitazone.

Yu L, Li H, Zhang C, Zhang Q, Guo J, Li J, Yuan H, Li L, Carmichael PL, Peng S.Environ Toxicol Pharmacol. Volume 74, February 2020, 103296. IF=3.292

7.  食品成分的安全性評估：毒性動力學方法的實用性和相關性

Food ingredient safety evaluation: Utility and relevance of toxicokinetic methods.

Kabadi SV, Zang Y, Fisher JW, Smith N, Whiteside C, Aungst J. Toxicol Appl Pharmacol. Volume 382, 1 November 2019, 114759. IF=3.347

8.  三環唑類殺菌劑口服后在嚙齒類動物的ADME曲線：評估化合物對人類健康安全性的重要綜述

The ADME profile of the fungicide tricyclazole in rodent via the oral route: A critical review for human health safety assessment.

Corvaro M, Bartels M. Regul Toxicol Pharmacol. Volume 108, November 2019, 104438. IF=2.652

9.  通過體外劑量-效應數據，整合藥代動力學和體內暴露的信息，從而對化學品進行篩選和排序的分層方法

Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data.

Leonard JA, Tan YM. Computational Toxicology. Volume 12, November 2019, 100101. CiteScore=2.5

10.  雙酚A的微小結構修飾變化導致HepG2細胞的強烈生理反應

Minor structural modifications of bisphenol A strongly affect physiological responses of HepG2 cells.

Padberg F, Tarnow P, Luch A, Zellmer S. Arch Toxicol. May 4, 2019. IF=5.059

11.  通過計算機預測的方法輔助開發和評估基于生理的動力學模型

In silico resources to assist in the development and evaluation of physiologically-based kinetic models.

Madden JC, Pawar G, Cronin MTD, Webb S, Tan YM, Paini A. Computational Toxicology. Mar 5, 2019. CiteScore=2.5

12.  通過體外-計算機模擬的方法預測藥物在體內的性能

In vitro – in silico approach for the prediction of in vivo performance of drugs.

do Vale Correia C, de Sousa Vale NF, Urtti A, Yliperttula M. Eur J Pharm Sci. Feb 12, 2019. IF=3.616

13.  化妝品安全評估中毒理學關注內部閾值（iTTC）面臨的挑戰：化妝品歐洲iTTC研討會的相關討論要點

Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop.

Ellison CA, Blackburn KL, Carmichael PL, Clewell HJ 3rd, Cronin MTD, Desprez B, Escher SE, Ferguson SS, Gregoire SL, Hewitt NJ, Hollnagel HM, Klaric M, Patel A, Salhi S, Schepky A, Schmitt BG, Wambaugh JF, Worth A. Regul Toxicol Pharmacol. Jan 28, 2019. IF=2.652

14.  使用人體生物監測和毒代動力學數據評估操作者暴露于haloxyfop的PBTK模型

PBTK model for assessment of operator exposure to haloxyfop using human biomonitoring and toxicokinetic data.

Cooper AB, Aggarwal M, Bartels MJ, Morriss A, Terry C, Lord GA, Gant TW. Regul Toxicol Pharmacol. Dec 10, 2018. IF=2.652

15.  生理動力學模型在解決環境化學混合物中的作用-綜述

Role of Physiologically Based Kinetic modelling in addressing environmental chemical mixtures – a review.

Desalegn A, Bopp S, Asturiol D, Lamon L, Worth A, Paini A. Computational Toxicology.  Oct 1, 2018. CiteScore=2.5

16.  用現代標準評價2-乙基己基丙烯酸酯的皮膚致癌性研究

Critical Evaluation of 2-Ethylhexyl Acrylate Dermal Carcinogenicity Studies Using Contemporary Criteria.

Murphy S, Ellis-Hutchings R, Finch L, Welz S, Wiench K. Toxicol Lett. Sep 15, 2018.IF=3.569

17.     用于高通量篩選中優先順序和決策的體外到體內轉化IVIVE

In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M,et,al. Toxicol In Vitro. 2018 Mar;47:213-227. IF=2.959

18.  通過體外-體內轉化評估毒代動力學TK

Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics.

John F Wambaugh, Michael F Hughes, Caroline L Ring, Denise K MacMillan, Jermaine Ford, Timothy R Fennell, et al. Toxicol Sci. 2018 May; 163(1): 152–169.IF=3.703

19.  考察基于生理學的動力學模型實操的狀態，法規監管中模型應用面臨的挑戰

Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.

Paini A, Leonard JA, Kliment T, Tan YM, Worth A. Regul Toxicol Pharmacol. Nov 1, 2017. IF=2.652

20.  整合生命階段的生理藥代動力學PBPK模型與不良結果通路（AOPs）和環境暴露模型，以篩選對環境的危害

Integration of Life-Stage Physiologically-Based Pharmacokinetic (PBPK) Models with Adverse Outcome Pathways (AOPs) and Environmental Exposure Models to Screen for Environmental Hazards.

El-Masri H, Kleinstreuer N, Hines RN, Adams L, Tal T, Isaacs K, Wetmore BA, Tan YM. (2016). Toxicol Sci. May 4. IF=3.564

21.  使用高通量的體外數據，高通量暴露模型，生理藥代動力學/藥效模型，估算甲狀腺過氧化物酶抑制劑的體內暴露

Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-throughput In Vitro Data, High-throughput Exposure Modeling, and Physiologically-Based Pharmacokinetic / Pharmacodynamic Modeling.

Leonard JA, Tan YM, Gilbert M, Isaacs K, El-Masri H. (2016) Toxicol Sci. Feb 10.IF=3.703

22.  聚乙二醇化的維生素Eγ-生育三烯酚異構體：合成，表征，體外細胞毒性和口服生物利用度

PEGylated y-tocotrienol isomer of vitamin E: Synthesis, characterization, in vitro cytotoxicity, and oral bioavailability.

Abu-Fayyad A, Behery F, Sallam A, Alqahtani S, Ebrahim H, El Sayed KA, Kaddoumi A, Sylvester PW, Carroll JL, Cardelli JA, Nazzal S. Eur J Pharm Biophar. Oct 1, 2015. IF=4.604

23.  通過機制性的ToxCast線粒體抑制數據和口服生物利用度的模擬，預測化合物在多個物種中的急性毒性

Acute toxicity prediction in multiple species by leveraging mechanistic ToxCast mitochondrial inhibition data and simulation of oral bioavailability.

Bhhatarai B, Wilson DM, Bartels MJ, Chaudhuri S, Price PS, Carney EW. Toxicol Sci.Oct 1, 2015. IF=3.703

24.  21世紀的毒性測試（TT21C）的實施：使用毒性途徑進行安全決策并對原型進行風險評估取得的進展

Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.

Adeleye Y, Andersen M, Clewell R, Davies M, Dent M, Edwards S, Fowler P, Malcomber S, Nicol B, Scott A, Scott S, Sun B, Westmoreland C, White A, Zhang Q, Carmichael PL. (2014). Toxicology, Feb 25. IF=4.099

25.  新的抗腫瘤吡唑衍生化合物的生物藥劑學概況

Biopharmaceutical profiling of new antitumor pyrazole derivatives.

Anuta V, Nitulescu GM, Dinu-P?rvu CE, Olaru OT. (2014) Molecules. Oct 13;19(10):16381-401. IF=3.267

26.  轉化PK / PD模型，并用于評價候選藥物的心血管安全性：藥物開發中的方法和實例

Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.

Caruso A, Frances N, Meille C, Greiter-Wilke A, Hillebrecht A, Lave T. (2014). J Pharmacol Toxicol Methods. May 28. IF=2.252

27.  新型LTA4H抑制劑在大鼠中的睪丸分布和毒性

Testicular distribution and toxicity of a novel LTA4H inhibitor in rats.

Ward PD, La D. (2014) Toxicol Appl Pharmacol. Apr 22;278(1):26-30. IF=3.347

28.  用于評估菊酯類殺蟲劑對人體風險的QSAR和PBPK / PD模型的參數

Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.

Knaak JB, Dary CC, Zhang X, Gerlach RW, Tornero-Velez R, Chang DT, Goldsmith R, Blancato JN. (2012) Rev. Environ. Contam. Toxicol. IF=5.767

點擊查看其他文獻

• GastroPlus在FDA等法規部門的應用文章(2016-2020)